메뉴 건너뛰기




Volumn 5, Issue SUPPL. 1, 2013, Pages

Fluid biomarkers for diagnosing dementia: Rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOTROPIN; GAMMA SECRETASE; INTERLEUKIN 17; INTERLEUKIN 23; PROGRANULIN; SPHINGOMYELIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; VASCULOTROPIN;

EID: 84889068875     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt223     Document Type: Review
Times cited : (18)

References (107)
  • 3
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    • 11240971
    • Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Biomarkers Definitions Working Group, Clin Pharmacol Ther 2001 69 89 95 11240971
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 89-95
    • Definitions Working Group, B.1
  • 5
    • 77949423619 scopus 로고    scopus 로고
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    • 10.1038/nrneurol.2010.4 20157306
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144 10.1038/nrneurol.2010.4 20157306
    • (2010) Nat Rev Neurol , vol.6 , pp. 131-144
    • Blennow, K.1    Hampel, H.2    Weiner, M.3    Zetterberg, H.4
  • 9
    • 79956076567 scopus 로고    scopus 로고
    • Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • 10.1016/j.jalz.2011.03.004 21514247
    • Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH, Alzheimers Dement 2011 7 257 262 10.1016/j.jalz.2011.03.004 21514247
    • (2011) Alzheimers Dement , vol.7 , pp. 257-262
    • Jack Jr., C.R.1    Albert, M.S.2    Knopman, D.S.3    McKhann, G.M.4    Sperling, R.A.5    Carrillo, M.C.6    Thies, B.7    Phelps, C.H.8
  • 10
    • 0026597063 scopus 로고
    • Alzheimer's disease: The amyloid cascade hypothesis
    • 10.1126/science.1566067 1566067
    • Alzheimer's disease: the amyloid cascade hypothesis. Hardy JA, Higgins GA, Science 1992 256 184 185 10.1126/science.1566067 1566067
    • (1992) Science , vol.256 , pp. 184-185
    • Hardy, J.A.1    Higgins, G.A.2
  • 11
    • 0036861112 scopus 로고    scopus 로고
    • Testing times for the amyloid cascade hypothesis
    • DOI 10.1016/S0197-4580(02)00042-8, PII S0197458002000428
    • Testing times for the 'amyloid cascade hypothesis'. Hardy J, Neurobiol Aging 2002 23 1073 1074 10.1016/S0197-4580(02)00042-8 12470803 (Pubitemid 35447788)
    • (2002) Neurobiology of Aging , vol.23 , Issue.6 , pp. 1073-1074
    • Hardy, J.1
  • 12
    • 33847662852 scopus 로고    scopus 로고
    • Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide
    • DOI 10.1038/nrm2101, PII NRM2101
    • Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Haass C, Selkoe DJ, Nat Rev Mol Cell Biol 2007 8 101 112 10.1038/nrm2101 17245412 (Pubitemid 46432529)
    • (2007) Nature Reviews Molecular Cell Biology , vol.8 , Issue.2 , pp. 101-112
    • Haass, C.1    Selkoe, D.J.2
  • 14
    • 80053912909 scopus 로고    scopus 로고
    • Alzheimer's disease: Beta-amyloid plaque formation in human brain
    • 10.1002/syn.20957 21633975
    • Alzheimer's disease: beta-amyloid plaque formation in human brain. Seeman P, Seeman N, Synapse 2011 65 1289 1297 10.1002/syn.20957 21633975
    • (2011) Synapse , vol.65 , pp. 1289-1297
    • Seeman, P.1    Seeman, N.2
  • 16
    • 77954835300 scopus 로고    scopus 로고
    • High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
    • 10.1096/fj.09-150359 20339023
    • High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M, Faseb J 2010 24 2716 2726 10.1096/fj.09-150359 20339023
    • (2010) Faseb J , vol.24 , pp. 2716-2726
    • Fukumoto, H.1    Tokuda, T.2    Kasai, T.3    Ishigami, N.4    Hidaka, H.5    Kondo, M.6    Allsop, D.7    Nakagawa, M.8
  • 18
    • 84875370865 scopus 로고    scopus 로고
    • New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
    • 10.1016/j.jalz.2012.11.005 23375565
    • New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ, Alzheimers Dement 2013 9 99 112 10.1016/j.jalz.2012.11.005 23375565
    • (2013) Alzheimers Dement , vol.9 , pp. 99-112
    • Yang, T.1    Hong, S.2    O'Malley, T.3    Sperling, R.A.4    Walsh, D.M.5    Selkoe, D.J.6
  • 22
    • 79953747266 scopus 로고    scopus 로고
    • Plasma clusterin and the risk of Alzheimer disease
    • 10.1001/jama.2011.381 21467285
    • Plasma clusterin and the risk of Alzheimer disease. Schrijvers EMC, Koudstaal PJ, Hofman A, Breteler MMB, JAMA 2011 305 1322 1326 10.1001/jama.2011.381 21467285
    • (2011) JAMA , vol.305 , pp. 1322-1326
    • Schrijvers, E.M.C.1    Koudstaal, P.J.2    Hofman, A.3    Breteler, M.M.B.4
  • 23
  • 26
    • 34447275455 scopus 로고    scopus 로고
    • 42 levels, incident dementia, and mortality in Down syndrome
    • DOI 10.1001/archneur.64.7.1007
    • Elevated plasma beta-amyloid peptide Aβ(42) levels, incident dementia, and mortality in Down syndrome. Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R, Arch Neurol 2007 64 1007 1013 10.1001/archneur.64.7.1007 17620492 (Pubitemid 47048002)
    • (2007) Archives of Neurology , vol.64 , Issue.7 , pp. 1007-1013
    • Schupf, N.1    Patel, B.2    Pang, D.3    Zigman, W.B.4    Silverman, W.5    Mehta, P.D.6    Mayeux, R.7
  • 27
    • 33746291599 scopus 로고    scopus 로고
    • Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment
    • DOI 10.1016/j.neurobiolaging.2006.03.004, PII S0197458006000893
    • Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C, Neurobiol Aging 2006 27 904 905 10.1016/j.neurobiolaging.2006.03.004 16638622 (Pubitemid 44287903)
    • (2006) Neurobiology of Aging , vol.27 , Issue.6 , pp. 904-905
    • Pesaresi, M.1    Lovati, C.2    Bertora, P.3    Mailland, E.4    Galimberti, D.5    Scarpini, E.6    Quadri, P.7    Forloni, G.8    Mariani, C.9
  • 28
    • 74149089257 scopus 로고    scopus 로고
    • Evaluation of plasma Aβ(40) and Aβ(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
    • 10.1016/j.neurobiolaging.2008.03.027 18486992
    • Evaluation of plasma Aβ(40) and Aβ(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K, Neurobiol Aging 2010 31 357 367 10.1016/j.neurobiolaging.2008.03.027 18486992
    • (2010) Neurobiol Aging , vol.31 , pp. 357-367
    • Hansson, O.1    Zetterberg, H.2    Vanmechelen, E.3    Vanderstichele, H.4    Andreasson, U.5    Londos, E.6    Wallin, A.7    Minthon, L.8    Blennow, K.9
  • 29
    • 84863800460 scopus 로고    scopus 로고
    • Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis
    • 10.1001/archneurol.2011.1841 22451159
    • Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F, Arch Neurol 2012 69 824 831 10.1001/archneurol.2011.1841 22451159
    • (2012) Arch Neurol , vol.69 , pp. 824-831
    • Koyama, A.1    Okereke, O.I.2    Yang, T.3    Blacker, D.4    Selkoe, D.J.5    Grodstein, F.6
  • 30
    • 84873975872 scopus 로고    scopus 로고
    • Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems
    • 10.1186/alzrt155 23302773
    • Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. Galasko D, Golde TE, Alzheimers Res Ther 2013 5 1 5 10.1186/alzrt155 23302773
    • (2013) Alzheimers Res Ther , vol.5 , pp. 1-5
    • Galasko, D.1    Golde, T.E.2
  • 31
  • 32
    • 0025729415 scopus 로고
    • Microtubule destabilization and neurofilament phosphorylation precede dendritic sprouting after close axotomy of lamprey central neurons
    • Microtubule destabilization and neurofilament phosphorylation precede dendritic sprouting after close axotomy of lamprey central neurons. Hall GF, Lee VM, Kosik KS, Proc Natl Acad Sci USA 1991 88 5016 5020 10.1073/pnas.88.11.5016 2052584 (Pubitemid 21914674)
    • (1991) Proceedings of the National Academy of Sciences of the United States of America , vol.88 , Issue.11 , pp. 5016-5020
    • Hall, G.F.1    Lee, V.M.-Y.2    Kosik, K.S.3
  • 36
    • 33750999347 scopus 로고    scopus 로고
    • Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
    • DOI 10.1212/01.wnl.0000242732.06714.0f, PII 0000611420061114000016
    • Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B, Neurology 2006 67 1600 1604 10.1212/01.wnl.0000242732.06714.0f 17101890 (Pubitemid 44747930)
    • (2006) Neurology , vol.67 , Issue.9 , pp. 1600-1604
    • Ost, M.1    Nylen, K.2    Csajbok, L.3    Ohrfelt, A.O.4    Tullberg, M.5    Wikkelso, C.6    Nellgard, P.7    Rosengren, L.8    Blennow, K.9    Nellgard, B.10
  • 37
    • 0035910638 scopus 로고    scopus 로고
    • Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
    • DOI 10.1016/S0304-3940(00)01697-9, PII S0304394000016979
    • Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K, Neurosci Lett 2001 297 187 190 10.1016/S0304-3940(00)01697-9 11137759 (Pubitemid 32011305)
    • (2001) Neuroscience Letters , vol.297 , Issue.3 , pp. 187-190
    • Hesse, C.1    Rosengren, L.2    Andreasen, N.3    Davidsson, P.4    Vanderstichele, H.5    Vanmechelen, E.6    Blennow, K.7
  • 40
    • 77949423619 scopus 로고    scopus 로고
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    • 10.1038/nrneurol.2010.4 20157306
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144 10.1038/nrneurol.2010.4 20157306
    • (2010) Nat Rev Neurol , vol.6 , pp. 131-144
    • Blennow, K.1    Hampel, H.2    Weiner, M.3    Zetterberg, H.4
  • 43
    • 43049113533 scopus 로고    scopus 로고
    • Rating quality of evidence and strength of recommendations: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations
    • 10.1136/bmj.39489.470347.AD 18436948
    • Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, BMJ 2008 336 924 10.1136/bmj.39489.470347. AD 18436948
    • (2008) BMJ , vol.336 , pp. 924
    • Guyatt, G.H.1    Oxman, A.D.2    Vist, G.E.3    Kunz, R.4    Falck-Ytter, Y.5    Alonso-Coello, P.6    Schünemann, H.J.7
  • 44
    • 73449137232 scopus 로고    scopus 로고
    • Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe
    • 10.1111/j.1468-1331.2009.02753.x 19659752
    • Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Hort J, Bartos A, Pirttila T, Scheltens P, Eur J Neurol 2010 17 90 96 10.1111/j.1468-1331.2009.02753.x 19659752
    • (2010) Eur J Neurol , vol.17 , pp. 90-96
    • Hort, J.1    Bartos, A.2    Pirttila, T.3    Scheltens, P.4
  • 45
    • 84862128944 scopus 로고    scopus 로고
    • Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease
    • 10.1016/j.ymeth.2012.03.023 22503777
    • Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang J-H, Vanderstichele H, Trojanowski JQ, Shaw LM, Methods 2012 56 484 493 10.1016/j.ymeth.2012.03.023 22503777
    • (2012) Methods , vol.56 , pp. 484-493
    • Kang, J.-H.1    Vanderstichele, H.2    Trojanowski, J.Q.3    Shaw, L.M.4
  • 46
  • 48
    • 33745920161 scopus 로고    scopus 로고
    • Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
    • DOI 10.1038/nm1438, PII NM1438
    • Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM, Nat Med 2006 12 856 861 10.1038/nm1438 16799555 (Pubitemid 44050079)
    • (2006) Nature Medicine , vol.12 , Issue.7 , pp. 856-861
    • Bateman, R.J.1    Munsell, L.Y.2    Morris, J.C.3    Swarm, R.4    Yarasheski, K.E.5    Holtzman, D.M.6
  • 53
    • 62449262536 scopus 로고    scopus 로고
    • Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
    • 10.1001/archneurol.2008.596 19273758
    • Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, Pirttila T, Arch Neurol 2009 66 382 389 10.1001/archneurol.2008.596 19273758
    • (2009) Arch Neurol , vol.66 , pp. 382-389
    • Tapiola, T.1    Alafuzoff, I.2    Herukka, S.-K.3    Parkkinen, L.4    Hartikainen, P.5    Soininen, H.6    Pirttila, T.7
  • 54
    • 77956935120 scopus 로고    scopus 로고
    • Added diagnostic value of CSF biomarkers in differential dementia diagnosis
    • 10.1016/j.neurobiolaging.2008.10.017 19150153
    • Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Bastard NL, Martin J-J, Vanmechelen E, Vanderstichele H, Deyn PPD, Engelborghs S, Neurobiol Aging 2010 31 1867 1876 10.1016/j.neurobiolaging.2008. 10.017 19150153
    • (2010) Neurobiol Aging , vol.31 , pp. 1867-1876
    • Bastard, N.L.1    Martin, J.-J.2    Vanmechelen, E.3    Vanderstichele, H.4    Deyn, P.P.D.5    Engelborghs, S.6
  • 57
    • 32544435900 scopus 로고    scopus 로고
    • Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study
    • DOI 10.1016/S1474-4422(06)70355-6, PII S1474442206703556
    • Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, Lancet Neurol 2006 5 228 234 10.1016/S1474-4422(06)70355-6 16488378 (Pubitemid 43238346)
    • (2006) Lancet Neurology , vol.5 , Issue.3 , pp. 228-234
    • Hansson, O.1    Zetterberg, H.2    Buchhave, P.3    Londos, E.4    Blennow, K.5    Minthon, L.6
  • 60
    • 77954555375 scopus 로고    scopus 로고
    • Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: Implications for trial design
    • Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. van Rossum IA, Vos S, Handels R, Visser PJ, J Alzheimers Disease 2010 20 881 891
    • (2010) J Alzheimers Disease , vol.20 , pp. 881-891
    • Van Rossum, I.A.1    Vos, S.2    Handels, R.3    Visser, P.J.4
  • 61
    • 78650464378 scopus 로고    scopus 로고
    • Evaluation of CSF biomarkers as predictors of Alzheimer's disease: A clinical follow-up study of 4.7 years
    • 21504133
    • Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O, J Alzheimers Dis 2010 21 1119 1128 21504133
    • (2010) J Alzheimers Dis , vol.21 , pp. 1119-1128
    • Hertze, J.1    Minthon, L.2    Zetterberg, H.3    Vanmechelen, E.4    Blennow, K.5    Hansson, O.6
  • 62
    • 65449157673 scopus 로고    scopus 로고
    • Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype
    • 10.1159/000216841 19420940
    • Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund L-O, Lannfelt L, Ingelsson M, Dement Geriatr Cogn Disord 2009 27 458 464 10.1159/000216841 19420940
    • (2009) Dement Geriatr Cogn Disord , vol.27 , pp. 458-464
    • Blom, E.S.1    Giedraitis, V.2    Zetterberg, H.3    Fukumoto, H.4    Blennow, K.5    Hyman, B.T.6    Irizarry, M.C.7    Wahlund, L.-O.8    Lannfelt, L.9    Ingelsson, M.10
  • 64
    • 0037244487 scopus 로고    scopus 로고
    • Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment
    • DOI 10.1034/j.1600-0404.107.s179.9.x
    • Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K, Acta Neurol Scand 2003 107 47 51 10.1034/j.1600-0404.107.s179.9.x (Pubitemid 41737337)
    • (2003) Acta Neurologica Scandinavica , vol.107 , Issue.SUPPL. 179 , pp. 47-51
    • Andreasen, N.1    Vanmechelen, E.2    Vanderstichele, H.3    Davidsson, P.4    Blennow, K.5
  • 80
    • 54449085260 scopus 로고    scopus 로고
    • Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration
    • 10.1212/01.wnl.0000325058.10218.fc 18768919
    • Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G, Neurology 2008 71 1235 1239 10.1212/01.wnl.0000325058.10218.fc 18768919
    • (2008) Neurology , vol.71 , pp. 1235-1239
    • Ghidoni, R.1    Benussi, L.2    Glionna, M.3    Franzoni, M.4    Binetti, G.5
  • 83
    • 34249040510 scopus 로고    scopus 로고
    • Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance
    • DOI 10.1212/01.wnl.0000262031.18018.1a, PII 0000611420070522000008
    • Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF, Neurology 2007 68 1809 1814 10.1212/01.wnl.0000262031.18018.1a 17515542 (Pubitemid 46791393)
    • (2007) Neurology , vol.68 , Issue.21 , pp. 1809-1814
    • Bowman, G.L.1    Kaye, J.A.2    Moore, M.3    Waichunas, D.4    Carlson, N.E.5    Quinn, J.F.6
  • 84
    • 60549089053 scopus 로고    scopus 로고
    • Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants
    • 10.1001/archneurol.2008.533 19204157
    • Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV, Arch Neurol 2009 66 208 215 10.1001/archneurol.2008.533 19204157
    • (2009) Arch Neurol , vol.66 , pp. 208-215
    • Appleby, B.S.1    Appleby, K.K.2    Crain, B.J.3    Onyike, C.U.4    Wallin, M.T.5    Rabins, P.V.6
  • 85
    • 67649386714 scopus 로고    scopus 로고
    • Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    • 10.1002/gps.2195 19123199
    • Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? Wallin ÅK, Hansson O, Blennow K, Londos E, Minthon L, Int J Geriatr Psychiatry 2009 24 638 647 10.1002/gps.2195 19123199
    • (2009) Int J Geriatr Psychiatry , vol.24 , pp. 638-647
    • Wallin, Å.1    Hansson, O.2    Blennow, K.3    Londos, E.4    Minthon, L.5
  • 87
    • 0026569503 scopus 로고
    • Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia
    • 10.1111/j.1600-0404.1992.tb04006.x 1574982
    • Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L, Acta Neurol Scand 1992 85 103 106 10.1111/j.1600-0404.1992. tb04006.x 1574982
    • (1992) Acta Neurol Scand , vol.85 , pp. 103-106
    • Fredman, P.1    Wallin, A.2    Blennow, K.3    Davidsson, P.4    Gottfries, C.G.5    Svennerholm, L.6
  • 89
    • 0038479920 scopus 로고    scopus 로고
    • Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia
    • DOI 10.1002/ana.10618
    • Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM, Ann Neurol 2003 54 115 119 10.1002/ana.10618 12838527 (Pubitemid 36764988)
    • (2003) Annals of Neurology , vol.54 , Issue.1 , pp. 115-119
    • Han, X.1    Fagan, A.M.2    Cheng, H.3    Morris, J.C.4    Xiong, C.5    Holtzman, D.M.6
  • 91
    • 0034815757 scopus 로고    scopus 로고
    • Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia
    • DOI 10.1016/S0047-6374(01)00306-2, PII S0047637401003062
    • Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Wallin A, Sjogren M, Mech Ageing Dev 2001 122 1937 1949 10.1016/S0047-6374(01)00306-2 11589912 (Pubitemid 32925104)
    • (2001) Mechanisms of Ageing and Development , vol.122 , Issue.16 , pp. 1937-1949
    • Wallin, A.1    Sjogren, M.2
  • 92
    • 82555184961 scopus 로고    scopus 로고
    • Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease
    • 21860087
    • Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U, J Alzheimers Dis 2011 27 665 676 21860087
    • (2011) J Alzheimers Dis , vol.27 , pp. 665-676
    • Bjerke, M.1    Zetterberg, H.2    Edman, A.3    Blennow, K.4    Wallin, A.5    Andreasson, U.6
  • 93
    • 0034846419 scopus 로고    scopus 로고
    • White matter damage is associated with matrix metalloproteinases in vascular dementia
    • 10.1161/01.STR.32.5.1162 11340226
    • White matter damage is associated with matrix metalloproteinases in vascular dementia. Rosenberg GA, Sullivan N, Esiri MM, Stroke 2001 32 1162 1168 10.1161/01.STR.32.5.1162 11340226
    • (2001) Stroke , vol.32 , pp. 1162-1168
    • Rosenberg, G.A.1    Sullivan, N.2    Esiri, M.M.3
  • 94
    • 7944234032 scopus 로고    scopus 로고
    • Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease
    • 10.1161/01.STR.0000127420.10990.76 15105518
    • Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA, Stroke 2004 35 159 e162 10.1161/01.STR.0000127420.10990.76 15105518
    • (2004) Stroke , vol.35
    • Adair, J.C.1    Charlie, J.2    Dencoff, J.E.3    Kaye, J.A.4    Quinn, J.F.5    Camicioli, R.M.6    Stetler-Stevenson, W.G.7    Rosenberg, G.A.8
  • 96
    • 0029417080 scopus 로고
    • Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
    • 10.1016/0304-3940(95)12192-7 8787820
    • Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P, Neurosci Lett 1995 202 17 20 10.1016/0304-3940(95)12192-7 8787820
    • (1995) Neurosci Lett , vol.202 , pp. 17-20
    • Blum-Degen, D.1    Müller, T.2    Kuhn, W.3    Gerlach, M.4    Przuntek, H.5    Riederer, P.6
  • 97
    • 79952199815 scopus 로고    scopus 로고
    • Does executive impairment define a frontal variant of Alzheimer's disease?
    • 10.1017/S1041610210001596 20719041
    • Does executive impairment define a frontal variant of Alzheimer's disease? Woodward M, Brodaty H, Boundy K, Ames D, Blanch G, Balshaw R, Int Psychogeriatr 2010 22 1280 1290 10.1017/S1041610210001596 20719041
    • (2010) Int Psychogeriatr , vol.22 , pp. 1280-1290
    • Woodward, M.1    Brodaty, H.2    Boundy, K.3    Ames, D.4    Blanch, G.5    Balshaw, R.6
  • 98
    • 77952954834 scopus 로고    scopus 로고
    • Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies
    • 10.1016/j.parkreldis.2010.02.015 20338799
    • Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Johansen KK, White LR, Sando SB, Aasly JO, Parkinsonism Relat Disord 2010 16 307 315 10.1016/j.parkreldis.2010.02.015 20338799
    • (2010) Parkinsonism Relat Disord , vol.16 , pp. 307-315
    • Johansen, K.K.1    White, L.R.2    Sando, S.B.3    Aasly, J.O.4
  • 99
    • 77953716788 scopus 로고    scopus 로고
    • Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
    • 10.1136/jnnp.2009.197483 20522869
    • Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T, J Neurol Neurosurg Psychiatry 2010 81 608 610 10.1136/jnnp.2009.197483 20522869
    • (2010) J Neurol Neurosurg Psychiatry , vol.81 , pp. 608-610
    • Kasuga, K.1    Tokutake, T.2    Ishikawa, A.3    Uchiyama, T.4    Tokuda, T.5    Onodera, O.6    Nishizawa, M.7    Ikeuchi, T.8
  • 105
    • 40949119905 scopus 로고    scopus 로고
    • Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases
    • DOI 10.1016/j.ymeth.2007.06.012, PII S1046202307001259
    • Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Otto M, Lewczuk P, Wiltfang J, Methods 2008 44 289 298 10.1016/j.ymeth.2007.06.012 18374272 (Pubitemid 351406506)
    • (2008) Methods , vol.44 , Issue.4 , pp. 289-298
    • Otto, M.1    Lewczuk, P.2    Wiltfang, J.3
  • 106
    • 77952477706 scopus 로고    scopus 로고
    • Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: United we stand, divided we fall
    • 20201744
    • Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Mattsson N, Blennow K, Zetterberg H, Clin Chem Lab Med 2010 48 603 607 20201744
    • (2010) Clin Chem Lab Med , vol.48 , pp. 603-607
    • Mattsson, N.1    Blennow, K.2    Zetterberg, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.